Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography

Although alterations of serotonin (5-HT) system functioning have been proposed for a variety of psychiatric disorders, a direct method quantitatively assessing 5-HT release capacity in the living human brain is still lacking. Therefore, we evaluated a novel method to assess 5-HT release capacity in vivo using dexfenfluramine challenge and [(18)F]altanserin positron emission tomography (PET). Thirteen healthy male subjects received placebo and single oral doses of 40 mg (n = 6) or 60 mg (n = 7) of the potent 5-HT releaser dexfenfluramine separated by an interval of 14 days. Three further subjects received placebo on both days. Two hours after placebo/drug administration, 250 MBq of the 5-HT(2A) receptor selective PET-radiotracer [(18)F]altanserin was administered intravenously as a 30s bolus. Dynamic PET data were subsequently acquired over 90 min. Moreover, arterial blood samples were drawn for measurement of total activity and metabolite correction of the input function. Dexfenfluramine as well as cortisol and prolactin plasma concentration-time profiles was quantitatively determined. Tracer distribution volumes for five volumes-of-interest (prefrontal and occipital cortex, insula, thalamus, caudatum) were calculated by the Logan plot and a 2-tissue compartment model. Dexfenfluramine dose-dependently decreased the total distribution volume of [(18)F]altanserin in cortical regions independent of the PET modeling approach. Cortisol and prolactin plasma concentrations were dose-dependently increased by dexfenfluramine. The decrease in cortical [(18)F]altanserin receptor binding under dexfenfluramine was correlated with the increase of plasma prolactin. These data suggest that the combination of a dexfenfluramine-induced 5-HT release and subsequent assessment of 5-HT(2A) receptor availability with [(18)F]altanserin PET is suitable to measure cortical 5-HT release capacity in the human brain.

[1]  J. Olesen,et al.  Induction of prolonged tenderness in patients with tension‐type headache by means of a new experimental model of myofascial pain , 2003, European journal of neurology.

[2]  L. Farde,et al.  Short Communication Fenfluramine-Induced Serotonin Release Decreases ( 11 C)AZ10419369 Binding to 5-HT 1B -Receptors in the Primate Brain , 2010 .

[3]  L. Farde,et al.  Fenfluramine‐induced serotonin release decreases [11C]AZ10419369 binding to 5‐HT1B‐receptors in the primate brain , 2010, Synapse.

[4]  Søren Holm,et al.  [18F]altanserin Binding to Human 5HT2A Receptors is Unaltered after Citalopram and Pindolol Challenge , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  A Rieutord,et al.  The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine. , 2003, British journal of clinical pharmacology.

[6]  Michael H. Baumann,et al.  3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings , 2006, Psychopharmacology.

[7]  J. Leysen,et al.  Use of 5-HT Receptor Agonists and Antagonists for the Characterization of Their Respective Receptor Sites , 1989 .

[8]  Laurent Descarries,et al.  Toward brain imaging of serotonin 5-HT1A autoreceptor internalization , 2004, NeuroImage.

[9]  G Westera,et al.  GMP-compliant radiosynthesis of [18F]altanserin and human plasma metabolite studies. , 2009, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[10]  John F. Young,et al.  Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations. , 2003, Neurotoxicology.

[11]  Paul J. Harrison,et al.  Expression of serotonin 5‐HT2A receptors in the human cerebellum and alterations in schizophrenia , 2001, Synapse.

[12]  O Pelkonen,et al.  Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2. , 1998, Pharmacogenetics.

[13]  A. Meneses,et al.  5-HT system and cognition , 1999, Neuroscience & Biobehavioral Reviews.

[14]  R. Rothman,et al.  Therapeutic potential of monoamine transporter substrates. , 2006, Current topics in medicinal chemistry.

[15]  D. Charney,et al.  Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent. , 1999, Nuclear medicine and biology.

[16]  H. Müller-Gärtner,et al.  Distribution of 5HT2A receptors in the human brain: comparison of data in vivo and post mortem , 2002, Nuklearmedizin.

[17]  Nic Gillings,et al.  Binding characteristics of the 5‐HT2A receptor antagonists altanserin and MDL 100907 , 2005, Synapse.

[18]  B. Roth,et al.  Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor , 1996, Psychopharmacology.

[19]  Hans Herzog,et al.  Cognition-induced modulation of serotonin in the orbitofrontal cortex: A controlled cross-over PET study of a delayed match-to-sample task using the 5-HT2a receptor antagonist [18F]altanserin , 2011, NeuroImage.

[20]  Michael H. Baumann,et al.  (+)-Fenfluramine and Its Major Metabolite, (+)-Norfenfluramine, Are Potent Substrates for Norepinephrine Transporters , 2003, Journal of Pharmacology and Experimental Therapeutics.

[21]  R. Rothman,et al.  Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. , 1999, Circulation.

[22]  P Andolz,et al.  Characterization and regional binding of human sperm monoclonal antibodies. , 1994, Hybridoma.

[23]  Samarjit Bhattacharyya,et al.  Internalization and recycling of 5-HT2A receptors activated by serotonin and protein kinase C-mediated mechanisms , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Murphy,et al.  Peripheral Indices of Central Serotonin Function in Humans , 1990, Annals of the New York Academy of Sciences.

[25]  J Weissenburger,et al.  The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. , 1995, British journal of clinical pharmacology.

[26]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[27]  Andreas Meisel,et al.  Molecular and Cellular Mechanisms of Ecstasy-Induced Neurotoxicity: An Overview , 2009, Molecular Neurobiology.

[28]  Robbert Jan Verkes,et al.  Saccadic peak velocity and EEG as end‐points for a serotonergic challenge test , 2002, Human psychopharmacology.

[29]  J. Cadet,et al.  Substituted Amphetamines That Produce Long‐Term Serotonin Depletion in Rat Brain (“Neurotoxicity”) Do Not Decrease Serotonin Transporter Protein Expression , 2004, Annals of the New York Academy of Sciences.

[30]  R. Lefkowitz,et al.  The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. , 2002, Journal of cell science.

[31]  Samarjit Bhattacharyya,et al.  Activation, internalization, and recycling of the serotonin 2A receptor by dopamine , 2006, Proceedings of the National Academy of Sciences.

[32]  Jacob Geday,et al.  Serotonin modulation of cerebral blood flow measured with positron emission tomography (PET) in humans , 2005, Synapse.

[33]  Barry L. Jacobs,et al.  Handbook of the behavioral neurobiology of serotonin , 2010 .

[34]  Vijay Dhawan,et al.  Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects , 2002, Synapse.

[35]  J. Maloteaux,et al.  Characterization and regional distribution of serotonin S2-receptors in human brain , 1983, Brain Research.

[36]  Jeih-San Liow,et al.  D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: A PET study in a receptor internalization-deficient mouse model , 2010, NeuroImage.

[37]  S Garattini,et al.  Oral kinetics of dexfenfluramine and dexnorfenfluramine in non-human primates. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[38]  David Eidelberg,et al.  Serotonin Modulation of Cerebral Glucose Metabolism in Depressed Older Adults , 2009, Biological Psychiatry.

[39]  R. Porter,et al.  Functional characterization of agonists at recombinant human 5‐HT2A, 5‐HT2B and 5‐HT2C receptors in CHO‐K1 cells , 1999, British journal of pharmacology.

[40]  Wolfgang Gaebel,et al.  Influence of synaptic serotonin level on [18F]altanserin binding to 5HT2 receptors in man , 2003, Behavioural Brain Research.

[41]  E. sanders-Bush,et al.  Serotonin and brain development. , 2004, International review of neurobiology.

[42]  Gwenn S. Smith,et al.  Analyses of [18F]altanserin bolus injection PET data. II: Consideration of radiolabeled metabolites in humans , 2001, Synapse.

[43]  Alan A. Boulton,et al.  Drugs as tools in neurotransmitter research , 1989 .

[44]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[45]  Sylvain Houle,et al.  Neuromodulation of frontal and temporal cortex by intravenous d-fenfluramine: an [15O]H2O PET study in humans , 1996, Neuroscience Letters.

[46]  J. Palacios,et al.  Serotonin receptors in the human brain—IV. Autoradiographic mapping of serotonin-2 receptors , 1987, Neuroscience.

[47]  Julie K. Staleya,et al.  PII: S0969-8051(00)00212-2 , 2001 .

[48]  Sylvain Houle,et al.  Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. , 2010, Brain : a journal of neurology.

[49]  Laurent Descarries,et al.  Acute Treatment with the Antidepressant Fluoxetine Internalizes 5-HT1A Autoreceptors and Reduces the In Vivo Binding of the PET Radioligand [18F]MPPF in the Nucleus Raphe Dorsalis of Rat , 2004, The Journal of Neuroscience.

[50]  R. Elliott,et al.  Assessing human 5-HT function in vivo with pharmacoMRI , 2008, Neuropharmacology.

[51]  G. Kennett,et al.  Pharmacological characterisation of the agonist radioligand binding site of 5-HT2A, 5-HT2B and 5-HT2C receptors , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[52]  S Kasper,et al.  Influence of escitalopram treatment on 5-HT1A receptor binding in limbic regions in patients with anxiety disorders , 2009, Molecular Psychiatry.

[53]  Gitte M Knudsen,et al.  Measuring Endogenous 5-HT Release by Emission Tomography: Promises and Pitfalls , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[54]  B. Largent,et al.  Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. , 2000, Molecular pharmacology.

[55]  M. Laruelle.  Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[56]  Olaf B. Paulson,et al.  A database of [18F]-altanserin binding to 5-HT2A receptors in normal volunteers: normative data and relationship to physiological and demographic variables , 2004, NeuroImage.

[57]  S. Gilman,et al.  11C-DTBZ and 18F-FDG PET measures in differentiating dementias. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[58]  J. Maloteaux,et al.  Regional and Cortical Laminar Distributions of Serotonin S2, Benzodiazepine, Muscarinic, and Dopamine D2 Receptors in Human Brain , 1984, Journal of neurochemistry.

[59]  Bryan L Roth,et al.  Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists , 2001, Brain Research Bulletin.

[60]  Charles F. Reynolds,et al.  Reduced binding of [ 18 F ]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction , 1998, Brain Research.

[61]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[62]  W. Slikker,et al.  Acute Effects of Dexfenfluramine (d‐FEN) and Methylenedioxymethamphetamine (MDMA) before and after Short‐Course, High‐Dose Treatment , 1998, Annals of the New York Academy of Sciences.

[63]  A. Bauer,et al.  Acute S-ketamine application does not alter cerebral [18F]altanserin binding: a pilot PET study in humans , 2007, Journal of Neural Transmission.

[64]  J Booij,et al.  Investigating serotonergic function using positron emission tomography: overview and recent findings. , 2010, Current pharmaceutical design.

[65]  P. Maquet,et al.  Serotonin 5HT2 Receptor Imaging in the Human Brain Using Positron Emission Tomography and a New Radioligand, [18F]Altanserin: Results in Young Normal Controls , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[66]  Yogesh K. Dwivedi,et al.  Quantitation of 5HT2A receptor mRNA in human postmortem brain using competitive RT‐PCR , 1998, Neuroreport.

[67]  B. Roth,et al.  Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.

[68]  R Todd Ogden,et al.  In vivo Serotonin-Sensitive Binding of [11C]CUMI-101: A Serotonin 1A Receptor Agonist Positron Emission Tomography Radiotracer , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[69]  D. Nutt,et al.  Impulsiveness and the prolactin response to d-fenfluramine , 2000, Psychopharmacology.

[70]  J. Palacios,et al.  Human striosomes are enriched in 5‐HT2A receptors: autoradiographical visualization with [3H]MDL100,907, [125I](±)DOI and [3H]ketanserin , 1999, The European journal of neuroscience.